News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Kalkine Media Macro sensitivity
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.
This article provides a comprehensive overview of Enlight Renewable Energy Ltd (ENLT) stock, including its current price, market capitalization, performance metrics, and key financial figures. It also details the company's profile, analyst ratings, and major shareholders. The stock is currently trading at 85.440 USD …
Sharemaestro market context Trend signal active 52 weeks +182.0%Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 9:00 a.m. ET CALL PARTICIPANTS General Counsel - David Sigmon Chief Executive Officer - Greg Richardson Chairman of the Board - David Einhorn Chief Financial Officer - Faramarz Romer Full Conference Call Transcript …
Wall Street Zen upgraded Maplight Therapeutics (NASDAQ:MPLT) from "strong sell" to "sell," though the stock still holds a consensus "Moderate Buy" rating with an average price target of $29.67. The company recently reported better-than-expected quarterly EPS of -$1.32, and an insider director purchased 15,620 …
LightWave Acquisition Corp. (LWAC), a Cayman Islands SPAC, reported a net income of $3.39 million for the first half of 2026, primarily from earnings on its Trust Account investments. Despite this income, the company flagged substantial doubt about its ability to continue as a …
LIGT3 Fórum | Ações Light ON Investing.com Brasil - Finanças, Câmbio e Investimentos
nLIGHT, Inc. reported improved Q2 2026 results with higher revenue and reduced net loss, alongside Q3 revenue guidance of US$63 million to US$73 million. This performance, especially in the defense sector with new high-energy laser systems, suggests a potential shift towards consistent profitability. The …
Blaize Holdings saw a significant stock crash of 45% after cutting its 2026 revenue guidance from $130 million to $43 million due to slower order conversion and higher memory pricing. Meanwhile, nLIGHT experienced a modest 4% bounce after a brutal week-long selloff driven by …
Lightwave Logic, Inc. reported its Q2 2026 financial results, showing a modest increase in revenue to $32.8K, up from $25.6K in Q2 2025. The company's net loss widened to $6.614M, compared to $4.967M in the prior-year quarter, while basic and diluted loss per share …
Lightwave Logic (NASDAQ: LWLG) reported a wider net loss of $6.6 million for Q2 2026 and $12.9 million for the six-month period, primarily due to increased investment in R&D and general and administrative costs. Despite the losses, the company significantly strengthened its liquidity to …
The average 12-month price target for MapLight Therapeutics, Inc. (MPLT) stock has been revised down slightly to $28.77 from $29.31, based on estimates from 13 analysts. This new target suggests a significant 148% potential upside from its Aug. 13 closing price. The consensus rating …
Investing.com reports on a Form 8K filing by MapLight Therapeutics Inc. for August 13th. The article mentions the company's stock symbol MPLT and its daily performance, showing a 1.47% increase.
Company Logo Accelerating urban construction, strict energy-efficiency mandates, and rapid adoption of connected LED systems highlighted by Havells India's 18.9% revenue surge to ₹6,572 crore, Beacon Lighting Group's record A$176.3 million H1 sales, and ongoing smart lighting expansions from Signify, Opple Lighting, and Panasonic …
Sharemaestro market context Price below Trend Line 52 weeks -9.1%MapLight Therapeutics Inc (NASDAQ:MPLT) shares increased by 5.2% following the announcement of a $150 million private placement financing. The company plans to use the proceeds to advance ML-007C-MA, supporting its VISTA Phase 2 study in Alzheimer’s disease psychosis and the ZEPHYR-2 registrational Phase 3 …
nLIGHT (LASR) reported strong Q2 2026 results with record revenue, gross margin, and adjusted EBITDA, driven by growth in defense and advanced manufacturing markets. The company highlighted the significant Joint Laser Weapon System (JLWS) contract award as a strategic milestone, building on its HADES …
LightInTheBox Holding Co., Ltd. (NYSE:LITB) successfully completed a private placement, raising approximately $5.49 million in gross proceeds by issuing 21,397,409 ordinary shares. Chairman and CEO Jian He invested $1.09 million in the financing, increasing his beneficial ownership to about 24.1%. The company plans to …
MapLight Therapeutics (MPLT) reported a net loss of $60.2 million and a loss per share of $(1.32) for the second quarter of 2026, remaining pre-revenue. The increased loss compared to Q2 2025 was due to a significant ramp in clinical trial activity and operational …
LightInTheBox Holding Co., Ltd. (LITB) announced the completion of a private placement, raising approximately $5.49 million to accelerate its AI-driven strategic transformation. Chairman and CEO Jian He invested $1.09 million, increasing his beneficial ownership to 24.1%. The company plans to use the proceeds to …
MapLight Therapeutics has reported its financial results for Q2 2026, highlighting positive outcomes from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, which is now advancing to Phase 3. The company is primarily focusing its resources on ML-007C-MA, with ongoing enrollment for the …
Search by ticker symbol or company name and select a result to open its chart.